{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:02:29Z","timestamp":1789725749698,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Korea Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences in Space Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lssr.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:53:51Z","timestamp":1783922031000},"page":"45-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Re-evaluating pharmaceutical stability in space: A biomedical and regulatory science framework for long-duration missions"],"prefix":"10.1016","volume":"52","author":[{"given":"Ju Eun","family":"Seol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Hargens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-3425","authenticated-orcid":false,"given":"Jin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lssr.2026.07.002_bib0001","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fmicb.2018.00310","article-title":"Spaceflight modifies Escherichia coli gene expression in response to antibiotic exposure and reveals role of oxidative stress response","volume":"9","author":"Aunins","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.lssr.2026.07.002_bib0002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41526-019-0075-2","article-title":"Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding","volume":"5","author":"Blue","year":"2019","journal-title":"NPJ Microgravity"},{"key":"10.1016\/j.lssr.2026.07.002_bib0003","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41526-019-0076-1","article-title":"Limitations in predicting radiation-induced pharmaceutical instability during long-duration spaceflight","volume":"5","author":"Blue","year":"2019","journal-title":"NPJ Microgravity"},{"key":"10.1016\/j.lssr.2026.07.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/10806032261426910","article-title":"Comparative analysis of pharmaceutical content following spaceflight and vacuum exposure during commercial extravehicular activity","author":"Brawley","year":"2026","journal-title":"Wilderness Environ. Med."},{"key":"10.1016\/j.lssr.2026.07.002_bib0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41526-023-00275-2","article-title":"NASA space flight human-system standard: enabling human spaceflight missions by supporting astronaut health, safety, and performance","volume":"9","author":"Childress","year":"2023","journal-title":"NPJ Microgravity"},{"key":"10.1016\/j.lssr.2026.07.002_bib0006","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41526-024-00414-3","article-title":"Expiration analysis of the international space station formulary for exploration mission planning","volume":"10","author":"Diaz","year":"2024","journal-title":"NPJ Microgravity"},{"key":"10.1016\/j.lssr.2026.07.002_bib0007","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1208\/s12248-011-9270-0","article-title":"Evaluation of physical and chemical changes in pharmaceuticals flown on space missions","volume":"13","author":"Du","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.lssr.2026.07.002_bib0008","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/329059a0","article-title":"Gravitational haemodynamics and oedema prevention in the giraffe","volume":"329","author":"Hargens","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.lssr.2026.07.002_bib0009","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1152\/japplphysiol.00935.2015","article-title":"Long-duration bed rest as an analog to microgravity","volume":"120","author":"Hargens","year":"2016","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.lssr.2026.07.002_bib0010","unstructured":"International Council for Harmonisation (ICH), 1996. ICH Q1B: photostability testing of new drug substances and medicinal products. https:\/\/database.ich.org\/sites\/default\/files\/Q1B%20Guideline.pdf."},{"key":"10.1016\/j.lssr.2026.07.002_bib0011","unstructured":"International Council for Harmonisation (ICH), 2003. ICH Q1A(R2): stability testing of new drug substances and products. https:\/\/database.ich.org\/sites\/default\/files\/Q1A%28R2%29%20Guideline.pdf."},{"key":"10.1016\/j.lssr.2026.07.002_bib0012","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ejps.2017.05.025","article-title":"Drugs in space: pharmacokinetics and pharmacodynamics in astronauts","volume":"109","author":"Kast","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.lssr.2026.07.002_bib0013","unstructured":"Korea Advanced Institute of Science and Technology (KAIST), 2021. KAI-KAIST signed MOU for aerospace technology research center. https:\/\/isc.kaist.ac.kr\/english\/sub0601\/view\/id\/106 (accessed 11 April 2026)."},{"key":"10.1016\/j.lssr.2026.07.002_bib0014","unstructured":"Korea Institute of Science and Technology (KIST), 2024. KIST and MFDS sign MOU to enhance regulatory science capabilities. https:\/\/nodrugzone.mfds.go.kr\/fileView.do?uniqueKey=cb00d1a0008a85e71a41b8741facbffe859055c2a7b18aa4c79dc07e37c98cad (accessed 11 April 2026)."},{"key":"10.1016\/j.lssr.2026.07.002_bib0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jpba.2016.12.040","article-title":"Impact of space environment on stability of medicines: challenges and prospects","volume":"136","author":"Mehta","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.lssr.2026.07.002_bib0016","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0094-5765(03)00207-8","article-title":"The European astronaut centre prepares for international space station operations","volume":"54","author":"Messerschmid","year":"2004","journal-title":"Acta Astronaut."},{"key":"10.1016\/j.lssr.2026.07.002_bib0017","unstructured":"Ministry of Food and Drug Safety (MFDS), 2021. Regulation for pharmaceutical approvals, notifications and reviews. (MFDS Notification No. 2021-90). https:\/\/www.mfds.go.kr\/eng\/brd\/m_18\/view.do?company_cd=&company_nm=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&page=1&seq=71524&srchFr=&srchTo=&srchTp=&srchWord=pharmaceutical+affairs. (accessed 11 April 2026)."},{"key":"10.1016\/j.lssr.2026.07.002_bib0018","unstructured":"NASA Exploration Medical Capability Program, 2023. NASA-FDA collaboration to enable safe use of pharmaceuticals in space. https:\/\/ntrs.nasa.gov\/api\/citations\/20250000735\/downloads\/ROI-FDA%20-%20IWS%20Talk-Final-2.pdf."},{"key":"10.1016\/j.lssr.2026.07.002_bib0019","unstructured":"NASA Human Research Program, 2024. Exploration medical capability strategy for drug stability: recommendations for spaceflight pharmaceutical development. NASA\/TP-20240001489. https:\/\/ntrs.nasa.gov\/api\/citations\/20240001489\/downloads\/ExMC%20Strat%20for%20Drug%20Stability%20-%20May%202024%20final%201.pdf."},{"key":"10.1016\/j.lssr.2026.07.002_bib0020","series-title":"Advancing the Discipline of Regulatory Science for Medical Product Development","article-title":"Challenges and opportunities in regulatory science","year":"2016"},{"issue":"1","key":"10.1016\/j.lssr.2026.07.002_bib0021","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1021\/ie990870t","article-title":"Strategic supply chain optimization for the pharmaceutical industries","volume":"40","author":"Papageorgiou","year":"2001","journal-title":"Ind. Eng. Chem. Res."},{"key":"10.1016\/j.lssr.2026.07.002_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/frspt.2025.1553854","article-title":"Microbial contamination and pharmaceutical stability in space environment: addressing dual challenge with innovative technologies and sustainable practices","volume":"6","author":"Patel","year":"2025","journal-title":"Front. Space Technol."},{"key":"10.1016\/j.lssr.2026.07.002_bib0023","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41526-025-00469-w","article-title":"The long-term stability of solid-state oral pharmaceuticals exposed to simulated intravehicular space radiation","volume":"11","author":"Plante","year":"2025","journal-title":"NPJ Microgravity"},{"key":"10.1016\/j.lssr.2026.07.002_bib0024","unstructured":"Putcha, L., Berens, K., Du, B., Daniels, V., 1993. Pharmacokinetics and pharmacodynamics in space. NASA-TP-3300. https:\/\/ntrs.nasa.gov\/api\/citations\/19930020313\/downloads\/19930020313.pdf."},{"key":"10.1016\/j.lssr.2026.07.002_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24926\/iip.v15i4.6385","article-title":"Advancing astropharmacy: PAR model and space pharmacy council to preparing pharmacists for space missions","volume":"15","author":"Raza","year":"2024","journal-title":"Innov. Pharm."},{"key":"10.1016\/j.lssr.2026.07.002_bib0026","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41526-023-00271-6","article-title":"The effect of long-term spaceflight on drug potency and the risk of medication failure","volume":"9","author":"Reichard","year":"2023","journal-title":"NPJ Microgravity"},{"key":"10.1016\/j.lssr.2026.07.002_bib0027","article-title":"To infinity and beyond: strategies for fabricating medicines in outer space","volume":"4","author":"Seoane-Via\u00f1o","year":"2022","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.lssr.2026.07.002_bib0028","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.compchemeng.2003.09.022","article-title":"Pharmaceutical supply chains: key issues and strategies for optimisation","volume":"28","author":"Shah","year":"2004","journal-title":"Comput. Chem. Eng."},{"key":"10.1016\/j.lssr.2026.07.002_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15560-w","article-title":"Increased core body temperature in astronauts during long-duration space missions","volume":"7","author":"Stahn","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lssr.2026.07.002_bib0030","unstructured":"U.S. Food and Drug Administration (FDA), 2025. 21 CFR Part 211 - current good manufacturing practice for finished pharmaceuticals. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-C\/part-211."},{"key":"10.1016\/j.lssr.2026.07.002_bib0031","unstructured":"U.S. Food and Drug Administration (FDA), National Aeronautics and Space Administration (NASA), 2018. Memorandum of understanding between the food and drug administration and the national aeronautics and space administration. https:\/\/www.fda.gov\/about-fda\/domestic-mous\/mou-225-18-027."},{"key":"10.1016\/j.lssr.2026.07.002_bib0032","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrrheum.2018.37","article-title":"Skeletal changes during and after spaceflight","volume":"14","author":"Vico","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.lssr.2026.07.002_bib0033","unstructured":"Waller, J.M., Rojdev, K., Shariff, K., Litteken, D.A., Hagen, R.A., Ross, A.J., 2020. Simulated galactic cosmic ray and solar particle event radiation exposure on pharmaceuticals. NASA Technical Reports Server. https:\/\/ntrs.nasa.gov\/citations\/20200003125."},{"issue":"11","key":"10.1016\/j.lssr.2026.07.002_bib0034","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1096\/fj.14-264838","article-title":"Medication use by U.S. crewmembers on the international space station","volume":"29","author":"Wotring","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.lssr.2026.07.002_bib0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1208\/s12248-015-9834-5","article-title":"Chemical potency and degradation products of medications stored over 550 Earth days at the international space station","volume":"18","author":"Wotring","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.lssr.2026.07.002_bib0036","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1152\/physrev.00017.2016","article-title":"Spaceflight-induced intracranial hypertension and visual impairment: pathophysiology and countermeasures","volume":"98","author":"Zhang","year":"2018","journal-title":"Physiol. Rev."}],"container-title":["Life Sciences in Space Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221455242600101X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221455242600101X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:08:33Z","timestamp":1789722513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221455242600101X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"alternative-id":["S221455242600101X"],"URL":"https:\/\/doi.org\/10.1016\/j.lssr.2026.07.002","relation":{},"ISSN":["2214-5524"],"issn-type":[{"value":"2214-5524","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-evaluating pharmaceutical stability in space: A biomedical and regulatory science framework for long-duration missions","name":"articletitle","label":"Article Title"},{"value":"Life Sciences in Space Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lssr.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Committee on Space Research (COSPAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}